CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases

Cases of interstitial lung disease and pneumonitis have been reported in patients receiving these CDK4/6 inhibitors indicated. Patients should be advised of the need to seek advice right away if they develop new or worsening respiratory symptoms.

Source:

Medicines and Healthcare products Regulatory Agency